Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid

Thyroid

Volumn 23, Issue 5, 2013, Pages 600-604

  Savvides, Panayiotis ^a,b   Nagaiah, Govardhanan ^c   Lavertu, Pierre ^a,b   Fu, Pingfu ^a,b   Wright, John J ^d   Chapman, Robert ^e   Wasman, Jay ^a,b   Dowlati, Afshin ^a,b   Remick, Scot C ^c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

ADULT; ADVANCED CANCER; ADVANCED THYROID ANAPLASTIC CARCINOMA; AGED; ANAPLASTIC CARCINOMA; ANAPLASTIC THYROID CANCER; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; DESQUAMATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG ERUPTION; FATIGUE; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; THYROID CARCINOMA; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; DRUG ERUPTIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RAF; SURVIVAL ANALYSIS; THYROID GLAND; THYROID NEOPLASMS;

EID: 84880553395     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0103     Document Type: Article

References (19)

1. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167.
2. Ain KB 1999 Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol 16:64-69.
3. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) 2010 AJCC Cancer Staging Manual, 7th edition. New York, NY: Springer Verlag.
4. Kim JH, Leeper RD 1987 Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 60:2372-2375.
5. Smallridge RC, Marlow LA, Copland JA 2009 Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16:17-44.
6. Fagin JA 1994 Molecular genetics of human thyroid neoplasms. Annu Rev Med 45:45-52.
7. Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC 2011 Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol 2011:5423-5458.
8. Kim S, Yazici YD, Calzada G, Wand ZY, Younes MN, Jasser SA, El-Naggar AK, Myers JN 2007 Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 6: 1785-1792.
9. Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yussuff N, Batt D, Fagin JA 2006 Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 12:1785-1793.
10. Salvatore G, De Falco V, Salerno P, Jiang Y, Garbi C, Ugolini C, Miccoli P, Basolo F, Castellone MD, Cirafici AM, Melillo RM, Fusco A, Bittner ML, Santoro M 2006 BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 12:1623-1629.
11. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR 2008 Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals crosscontamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93:4331-4341.
12. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719.
13. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE, Jr. , Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684.
14. Simon R 1989 Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10.
15. Tsai WY, Chi Y, Chen CM 2008 Interval estimation of binomial proportion in clinical trials with a two-stage design. Stat Med 27:15-35.
16. Are C, Shaha AR 2006 Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 13:453-464.
17. Wiseman SM, Loree TR, Rigual NR, Hicks WL Jr, Douglas WG, Anderson GR, Stoler DL 2003 Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck 25:662-670.
18. Chen L, Shen Y, Luo Q, Yu Y, Lu H, Zhu R 2011 Response to sorafenib at a low dose in patients with radioiodinerefractory pulmonary metastases from papillary thyroid carcinoma. Thyroid 21:119-124.
19. Mooney CJ, Nagaiah G, Fu P, Wasman JK, Cooney MM, Savvides PS, Bokar JA, Dowlati A, Wang D, Agarwala SS, Flick SM, Hartman PH, Ortiz JD, Lavertu PN, Remick SC 2009 A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 19:233-240.